Latest & greatest articles for anticoagulation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on anticoagulation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on anticoagulation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for anticoagulation

41. Management of Bleeding in Patients on Oral Anticoagulants

Management of Bleeding in Patients on Oral Anticoagulants EXPERT CONSENSUS DECISION PATHWAY 2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants A Report of the American College of Cardiology Solution Set Oversight Committee Writing Committee* Gordon F. Tomaselli, MD, FACC, Chair Kenneth W. Mahaffey, MD, FACC, Vice Chair Adam Cuker, MD, MS Paul P. Dobesh, PHARMD John U. Doherty, MD, FACC John W. Eikelboom, MBBS Roberta Florido, MD, MHS Ty J (...) . OAC Reversal Agents in Development 608 5.7. Considerations for Restarting Anticoagulation.. 608 Figure 4. Considerations for Restarting Anticoagulation ..609 5.7.1. ShouldAnticoagulationBeRestarted? ..608 Table 6. Original Indications for Anti- coagulation With High Thrombotic Risk .. 610 5.7.2. Timing of Anticoagulation Reinitiation ..609 Figure 5. Restart of Anticoagulation 611 Figure 6. Delaying Restart of Anticoagulation . 612 5.7.2. Patient Engagement in Restarting Anticoagulation ... .. 610

2020 American College of Cardiology

42. Meta-analysis study on direct oral anticoagulants vs warfarin therapy in atrial fibrillation and PCI: Dual or triple approach? Full Text available with Trip Pro

Meta-analysis study on direct oral anticoagulants vs warfarin therapy in atrial fibrillation and PCI: Dual or triple approach? Redirecting

2020 IJC Heart & Vasculature

43. Direct-acting oral anticoagulants (DOACs): reminder of bleeding risk, including availability of reversal agents

Direct-acting oral anticoagulants (DOACs): reminder of bleeding risk, including availability of reversal agents Direct-acting oral anticoagulants (DOACs): reminder of bleeding risk, including availability of reversal agents - GOV.UK Tell us whether you accept cookies We use about how you use GOV.UK. We use this information to make the website work as well as possible and improve government services. Accept all cookies You’ve accepted all cookies. You can at any time. Hide Search Guidance (...) and support Direct-acting oral anticoagulants (DOACs): reminder of bleeding risk, including availability of reversal agents Remain vigilant for signs and symptoms of bleeding complications during treatment with DOACs (apixaban, dabigatran, edoxaban, rivaroxaban), especially in patients with increased bleeding risks. Specific reversal agents are available for dabigatran (Praxbind▼, idarucizumab), and apixaban and rivaroxaban (Ondexxya▼, andexanet alfa). Published 29 June 2020 From: Therapeutic area

2020 MHRA Drug Safety Update

44. Direct Oral Anticoagulants for the Treatment of Acute Venous Thromboembolism Associated with Cancer: A Systematic Review and Meta-Analysis Full Text available with Trip Pro

Direct Oral Anticoagulants for the Treatment of Acute Venous Thromboembolism Associated with Cancer: A Systematic Review and Meta-Analysis Direct Oral Anticoagulants for the Treatment of Acute Venous Thromboembolism Associated with Cancer: A Systematic Review and Meta-Analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable (...) Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Thromb Haemost Actions . 2020 Jul;120(7):1128-1136. doi: 10.1055/s-0040-1712098. Epub 2020 May 4. Direct Oral Anticoagulants for the Treatment of Acute Venous Thromboembolism Associated with Cancer: A Systematic Review and Meta-Analysis , , , , , , , , , , , Affiliations Expand Affiliations 1 Internal Vascular and Emergency Medicine - Stroke Unit, University

2020 EvidenceUpdates

45. Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS Trial Full Text available with Trip Pro

Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS Trial Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable (...) Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Circulation Actions . 2020 Jun 9;141(23):1841-1854. doi: 10.1161/CIRCULATIONAHA.120.046448. Epub 2020 Mar 28. Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS Trial , , , , , , , , , , , , , , , , , , , , Collaborators, Affiliations Expand Collaborators COMPASS Steering

2020 EvidenceUpdates

46. Bleeding Risk in Nonvalvular Atrial Fibrillation Patients Receiving Direct Oral Anticoagulants and Warfarin: A Systematic Review and Meta-Analysis of Observational Studies Full Text available with Trip Pro

Bleeding Risk in Nonvalvular Atrial Fibrillation Patients Receiving Direct Oral Anticoagulants and Warfarin: A Systematic Review and Meta-Analysis of Observational Studies Thieme E-Journals - TH Open / Abstract EN Products TH Open Full-text search Not Logged In Username: Password: Year (Archive) 2020 Issues Related Journals Related Books Share / Bookmark CC BY 4.0 · TH Open 2020; 04(03): e145-e152 DOI: 10.1055/s-0040-1714918 Original Article Georg Thieme Verlag KG Stuttgart · New York Bleeding (...) Risk in Nonvalvular Atrial Fibrillation Patients Receiving Direct Oral Anticoagulants and Warfarin: A Systematic Review and Meta-Analysis of Observational Studies Yimin Pearl Wang 1 Division of Hematology, Department of Medicine, Western University, London, Ontario, Canada , Rohan Kehar 1 Division of Hematology, Department of Medicine, Western University, London, Ontario, Canada , Alla Iansavitchene 2 Library Services, London Health Sciences Centre, London, Ontario, Canada , 1 Division

2020 TH Open

47. DOES ANTICOAGULANT THROMBOPROPHYLAXIS INCREASE BLEEDING COMPLICATIONS IN SPINAL SURGERY AND SPINAL CORD INJURY? A SYSTEMATIC REVIEW AND META-ANALYSIS Full Text available with Trip Pro

DOES ANTICOAGULANT THROMBOPROPHYLAXIS INCREASE BLEEDING COMPLICATIONS IN SPINAL SURGERY AND SPINAL CORD INJURY? A SYSTEMATIC REVIEW AND META-ANALYSIS DOES ANTICOAGULANT THROMBOPROPHYLAXIS INCREASE BLEEDING COMPLICATIONS IN SPINAL SURGERY AND SPINAL CORD INJURY? A SYSTEMATIC REVIEW AND META-ANALYSIS × Notice As part of Open Journals’ initiatives, we create website for scholarly open access journals. If you are responsible for this journal and would like to know more about how to use (...) the editorial system, please visit our website at or send us an email to info@ejournalplus.com We will contact you soon Close Authors Print ISSN: Online ISSN: DOES ANTICOAGULANT THROMBOPROPHYLAXIS INCREASE BLEEDING COMPLICATIONS IN SPINAL SURGERY AND SPINAL CORD INJURY? A SYSTEMATIC REVIEW AND META-ANALYSIS " data-original-title="Anh TV Nguyen " > Anh TV Nguyen " data-original-title="Sonia Tran BMed " > Sonia Tran BMed " data-original-title="Thamer A Hamdan " > Thamer A Hamdan " data-original-title="Robin

2020 Basrah Journal of Surgery

48. Use of Anticoagulation in Patients with COVID-19 Infection Full Text available with Trip Pro

Use of Anticoagulation in Patients with COVID-19 Infection Use of Anticoagulation in Patients with COVID-19 Infection - CanadiEM Use of Anticoagulation in Patients with COVID-19 Infection In by Johnny Huang June 18, 2020 Introduction The novel coronavirus, known as COVID-19, was originally reported in a cluster of pneumonia cases in Wuhan (China) near the end of 2019 ​1​ . Over the next 6 months, COVID-19 has emerged as the world’s newest pandemic disease with over 7 million cases worldwide ​1 (...) and reduced fibrinogen levels, the distinguishing feature of COVID-19 pertains to thrombosis formation and inflammation without significant consumption of coagulation markers ​5​ . A case-series study showed an increased risk for VTE, mostly pulmonary embolism, among intensive care unit (ICU) patients with COVID-19-associated acute respiratory distress syndrome (ARDS) than those with non-COVID-19 ARDS, despite being on prophylactic anticoagulation ​9​ . Similar studies showed an incidence of VTE up to 30

2020 CandiEM

49. Psychotropic Drugs and Outcome in Patients Receiving Anticoagulant Therapy for Venous Thromboembolism

Psychotropic Drugs and Outcome in Patients Receiving Anticoagulant Therapy for Venous Thromboembolism Psychotropic Drugs and Outcome in Patients Receiving Anticoagulant Therapy for Venous Thromboembolism - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health National Library of Medicine National Center (...) Link Copy Actions Cite Share Permalink Copy Page navigation Thromb Haemost Actions . 2020 Apr;120(4):620-626. doi: 10.1055/s-0040-1708482. Epub 2020 Apr 14. Psychotropic Drugs and Outcome in Patients Receiving Anticoagulant Therapy for Venous Thromboembolism , , , , , , , , , , Affiliations Expand Affiliations 1 Department of Internal Medicine and Emergency, Parc Sanitari Sant Joan de Déu-Hospital General, Barcelona, Spain. 2 Department of Haematology and Bone Marrow Transplantation, Rambam Health

2020 EvidenceUpdates

50. Meta-Analysis Comparing Direct Oral Anticoagulants Versus Warfarin in Morbidly Obese Patients With Atrial Fibrillation

Meta-Analysis Comparing Direct Oral Anticoagulants Versus Warfarin in Morbidly Obese Patients With Atrial Fibrillation Meta-Analysis Comparing Direct Oral Anticoagulants Versus Warfarin in Morbidly Obese Patients With Atrial Fibrillation - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health National Library (...) displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Am J Cardiol Actions . 2020 Jul 1;126:23-28. doi: 10.1016/j.amjcard.2020.03.048. Epub 2020 Apr 8. Meta-Analysis Comparing Direct Oral Anticoagulants Versus Warfarin in Morbidly Obese Patients With Atrial Fibrillation , , , Affiliations Expand Affiliations 1 Department of Clinical Pharmacy, West Virginia University School of Pharmacy, Morgantown, West Virginia. Electronic address: kazuhiko.kido0322@gmail.com. 2

2020 EvidenceUpdates

51. Quality of life after switching from well-controlled vitamin K antagonist to direct oral anticoagulant: Little to GAInN Full Text available with Trip Pro

Quality of life after switching from well-controlled vitamin K antagonist to direct oral anticoagulant: Little to GAInN Quality of Life After Switching From Well-Controlled Vitamin K Antagonist to Direct Oral Anticoagulant: Little to GAInN - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health National (...) : Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Thromb Res Actions . 2020 Jun;190:69-75. doi: 10.1016/j.thromres.2020.04.007. Epub 2020 Apr 14. Quality of Life After Switching From Well-Controlled Vitamin K Antagonist to Direct Oral Anticoagulant: Little to GAInN , , , , , Affiliations Expand Affiliations 1 Department of Hematology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands; Certe Thrombosis

2020 EvidenceUpdates

52. Efficacy and safety of anticoagulant therapy in patients with chronic cirrhosis complicated with portal vein thrombosis: what should we expert from a meta-analysis? Full Text available with Trip Pro

Efficacy and safety of anticoagulant therapy in patients with chronic cirrhosis complicated with portal vein thrombosis: what should we expert from a meta-analysis? Efficacy and safety of anticoagulant therapy in patients with chronic cirrhosis complicated with portal vein thrombosis: what should we expert from a meta-analysis? | Research Square Browse Tools & Services Your Cart This preprint is under consideration at European Journal of Medical Research . A preprint is a preliminary version (...) of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice. Research Efficacy and safety of anticoagulant therapy in patients with chronic cirrhosis complicated with portal vein thrombosis: what should we expert from a meta-analysis? Yalin

2020 Research Square

53. Comparing Major Bleeding Risk in Outpatients With Atrial Fibrillation or Flutter by Oral Anticoagulant Type (from the National Cardiovascular Disease Registry`s Practice Innovation and Clinical Excellence Registry)

Comparing Major Bleeding Risk in Outpatients With Atrial Fibrillation or Flutter by Oral Anticoagulant Type (from the National Cardiovascular Disease Registry`s Practice Innovation and Clinical Excellence Registry) Comparing Major Bleeding Risk in Outpatients With Atrial Fibrillation or Flutter by Oral Anticoagulant Type (From the National Cardiovascular Disease Registry's Practice Innovation and Clinical Excellence Registry) - PubMed This site needs JavaScript to work properly. Please enable (...) when there aren't any new results Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Actions Cite Share Permalink Copy Page navigation Am J Cardiol Actions . 2020 May 15;125(10):1500-1507. doi: 10.1016/j.amjcard.2020.02.028. Epub 2020 Mar 5. Comparing Major Bleeding Risk in Outpatients With Atrial Fibrillation or Flutter by Oral Anticoagulant Type (From the National Cardiovascular Disease Registry's Practice Innovation and Clinical

2020 EvidenceUpdates

54. The Effect of Warfarin Administration Time on Anticoagulation Stability (INRange): A Pragmatic Randomized Controlled Trial Full Text available with Trip Pro

The Effect of Warfarin Administration Time on Anticoagulation Stability (INRange): A Pragmatic Randomized Controlled Trial The Effect of Warfarin Administration Time on Anticoagulation Stability (INRange): A Pragmatic Randomized Controlled Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health National (...) Permalink Copy Page navigation Ann Fam Med Actions . 2020 Jan;18(1):42-49. doi: 10.1370/afm.2488. The Effect of Warfarin Administration Time on Anticoagulation Stability (INRange): A Pragmatic Randomized Controlled Trial , , , , , , , Affiliations Expand Affiliations 1 Department of Family Medicine, University of Alberta, Edmonton, Alberta, Canada scott.garrison@ualberta.ca. 2 Department of Family Medicine, University of Alberta, Edmonton, Alberta, Canada. 3 Department of Anesthesiology, Pharmacology

2020 EvidenceUpdates

55. Direct Oral Anticoagulants and Low-Molecular Weight Heparin for Primary Prevention of Venous Thromboembolism in Cancer Patients: A Meta-Analysis Full Text available with Trip Pro

Direct Oral Anticoagulants and Low-Molecular Weight Heparin for Primary Prevention of Venous Thromboembolism in Cancer Patients: A Meta-Analysis Direct Oral Anticoagulants and Low-Molecular Weight Heparin for Primary Prevention of Venous Thromboembolism in Cancer Patients: A Meta-Analysis | C104. LATEST CLINICAL INVESTIGATIONS IN ACUTE AND CHRONIC THROMBOEMBOLISM DISORDERS OF THE PULMONARY CIRCULATION Cookies Notification This site uses cookies. By continuing to browse the site you are agreeing (...) to our use of cookies. Search Menu Connect With Us Search in: C104. LATEST CLINICAL INVESTIGATIONS IN ACUTE AND CHRONIC THROMBOEMBOLISM DISORDERS OF THE PULMONARY CIRCULATION > > > Direct Oral Anticoagulants and Low-Molecular Weight Heparin for Primary Prevention of Venous Thromboembolism in Cancer Patients: A Meta-Analysis Abstract American Journal of Respiratory and Critical Care Medicine 2020;201:A6045 Direct Oral Anticoagulants and Low-Molecular Weight Heparin for Primary Prevention of Venous

2020 C104. LATEST CLINICAL INVESTIGATIONS IN ACUTE AND CHRONIC THROMBOEMBOLISM DISORDERS OF THE PULMONARY CIRCULATION

56. Anticoagulation with or without Clopidogrel after Transcatheter Aortic-Valve Implantation. Full Text available with Trip Pro

Anticoagulation with or without Clopidogrel after Transcatheter Aortic-Valve Implantation. The roles of anticoagulation alone or with an antiplatelet agent after transcatheter aortic-valve implantation (TAVI) have not been well studied.We performed a randomized trial of clopidogrel in patients undergoing TAVI who were receiving oral anticoagulation for appropriate indications. Patients were assigned before TAVI in a 1:1 ratio not to receive clopidogrel or to receive clopidogrel for 3 months (...) from cardiovascular causes, ischemic stroke, or myocardial infarction (secondary composite 2), both tested for noninferiority (noninferiority margin, 7.5 percentage points) and superiority.Bleeding occurred in 34 of the 157 patients (21.7%) receiving oral anticoagulation alone and in 54 of the 156 (34.6%) receiving oral anticoagulation plus clopidogrel (risk ratio, 0.63; 95% confidence interval [CI], 0.43 to 0.90; P = 0.01); most bleeding events were at the TAVI access site. Non-procedure-related

2020 NEJM

57. Postoperative bleeding of therapeutic endoscopy in patients using direct oral anticoagulant or warfarin: A systematic review and meta-analysis Full Text available with Trip Pro

Postoperative bleeding of therapeutic endoscopy in patients using direct oral anticoagulant or warfarin: A systematic review and meta-analysis Inplasy Protocol 194 - INPLASY.COM International Platform of Registered Systematic Review and Meta-analysis Protocols Main Menu Share this: Copyright © 2021 INPLASY.COM Powered by INPLASY.COM

2020 INPLASY - International Platform of Registered Systematic Review Protocols

58. The association of fracture risk in atrial fibrillation patients and chronic anticoagulant therapy category: A systematic review and meta-analysis Full Text available with Trip Pro

The association of fracture risk in atrial fibrillation patients and chronic anticoagulant therapy category: A systematic review and meta-analysis Inplasy Protocol 148 - INPLASY.COM International Platform of Registered Systematic Review and Meta-analysis Protocols Main Menu Share this: Copyright © 2021 INPLASY.COM Powered by INPLASY.COM

2020 INPLASY - International Platform of Registered Systematic Review Protocols

59. Options for Peripartum Anticoagulation in Areas Affected by Shortage of Unfractionated Heparin

Options for Peripartum Anticoagulation in Areas Affected by Shortage of Unfractionated Heparin Options for Peripartum Anticoagulation in Areas Affected by Shortage of Unfractionated Heparin | ACOG Clinical Guidance Journals & Publications Patient Education Topics Featured Clinical Topics Hi, Featured Clinical Topics Clinical Guidance Options for Peripartum Anticoagulation in Areas Affected by Shortage of Unfractionated Heparin March 2020 Jump to Resources Share By reading this page you agree (...) to ACOG's Terms and Conditions. . Baxter Healthcare first reported to the U.S. Food and Drug Administration in November 2017 shortages of heparin sodium 2,000 international units/L in 0.9% weight/volume sodium chloride intravenous infusion, heparin sodium 2,000 USP units in 1,000 mL, and heparin sodium 1,000 USP units in 500 mL . The purpose of this practice advisory is to review options for anticoagulation in late gestation for practitioners in areas affected by a heparin shortage. In some cases

2020 American College of Obstetricians and Gynecologists

60. Covid-19: Clinical guide for the management of anticoagulant services during the coronavirus pandemic

Covid-19: Clinical guide for the management of anticoagulant services during the coronavirus pandemic Publications approval reference: 001559 NHS England and NHS Improvement Specialty guides for patient management during the coronavirus pandemic Clinical guide for the management of anticoagulant services during the coronavirus pandemic 31 March 2020 Version 1 As healthcare professionals we all have general responsibilities in relation to coronavirus and for these we should seek and act (...) on national and local guidelines. We also have a specific responsibility to ensure that anticoagulant care continues with the minimum burden on the NHS. We must engage with management and clinical teams planning the local response in our hospitals and across primary care. Anticoagulant services may not seem to be in the frontline with coronavirus but we do have a key role in continuing to keep patients on anticoagulants as safe as possible; this must be planned. In response to pressures on the NHS

2020 NHS England